Search clinical trials for: mTOR inhibitor with nab-paclitaxel

Total 5578 results

Abramson Cancer Center at Penn Medicine

Terminated

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Pancreatic Cancer

United States
Spanish Cooperative Group for the Treatment of...

Completed

Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (SEQUENCE)

Metastatic Pancreatic Adenocarcinoma

Spain
Fudan University
Merck Sharp & Dohme LLC

Recruiting

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Triple Negative Breast Cancer

China
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Stage III Non-small Cell Lung Cancer
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
NYU Langone Health
Celgene Corporation

Terminated

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma (rev/abraxane)

Relapsed or Refractory Multiple Myeloma

United States
Fudan University

Not yet recruiting

PD-1 Inhibitor Plus Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer (PTCA199-11)

Pancreatic Adenocarcinoma
Liaoning Tumor Hospital & Institute

Not yet recruiting

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Non Small Cell Lung Cancer
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

HER2-positive Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Breast Adenocarcinoma | Inflammatory Breast Carcinoma

United States
M.D. Anderson Cancer Center

Terminated

Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC)

HNSCC

United States
IRCCS San Raffaele
Bristol-Myers Squibb

Recruiting

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo)

Muscle-Invasive Bladder Carcinoma

Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Neoadjuvant Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

Salivary Gland Tumors | Salivary Gland Malignant Neoplasms

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer (ATNPA)

Locally Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer | Pancreatic Neoplasm

China
Washington University School of Medicine

Completed

Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies

Adenocarcinoma | Pancreatic Neoplasms

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Ireland, Italy, Mexico, Netherlands, Poland, Romania, Spain, Switzerland, United Kingdom
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer (CNN-BC)

Muscle-Invasive Bladder Carcinoma

Italy
Case Comprehensive Cancer Center

Completed

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
FibroGen

Active, not recruiting

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

Pancreatic Cancer Non-resectable

United States, Canada, France, Germany, Spain, Korea, Republic of, Austria, Italy, China, Belgium, Israel, United Kingdom
Fondazione Michelangelo

Completed

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1)

Invasive Ductal Breast Carcinoma

Spain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
Shantou Central Hospital

Recruiting

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Breast Cancer

China
MedSIR

Withdrawn

POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (POLTER)

Advanced Breast Cancer
Priyanka Sharma
Novartis Pharmaceuticals

Completed

BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Breast Cancer

United States
Liza Villaruz, MD

Completed

Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
University of Colorado, Denver
Cancer League of Colorado

Withdrawn

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Metastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene Mutation

United States
TransThera Sciences (Nanjing), Inc.

Recruiting

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Gastric Cancer | Prostate Cancer | Cholangiocarcinoma | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Small-cell Lung Cancer | Thyroid Cancer | Biliary Tract Cancer | Gallbladder Cancer | HER2-negative Breast Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Stage II-IIIB(N2) Non-small Cell Lung Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma

Gastric Cancer | Gastroesophageal-junction Cancer

China
Shanghai Henlius Biotech

Active, not recruiting

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Squamous Non Small Cell Lung Cancer

China, Turkey, United States, Georgia, Poland, Russian Federation, Ukraine
Riphah International University

Completed

Comparison of Motor Imagery Technique and Mime Therapy on Facial Expressions in Facial Palsy Patients

Facial Palsy

Pakistan
Beijing Tsinghua Chang Gung Hospital

Recruiting

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

NSCLC, Stage III

China
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
University of Valencia
Asociación Parkinson Valencia

Recruiting

Effects of Gait Rehabilitation With Motor Imagery in People With Parkinson's Disease (GAITimagery)

Parkinson Disease

Spain
University of Utah

Active, not recruiting

Assessing Adolescent Use of Nexplanon Over Time

Contraception

United States
M.D. Anderson Cancer Center

Active, not recruiting

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States
Fluart Innovative Vaccine Ltd, Hungary

Completed

A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects

Influenza

Hungary
UNC Lineberger Comprehensive Cancer Center
AstraZeneca; Rgenix, Inc.

Recruiting

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Non-Small Cell Lung Cancer

United States
GU Research Network, LLC

Withdrawn

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Pancreas Cancer

United States
DualityBio Inc.
BioNTech SE

Recruiting

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Metastatic Breast Cancer

United States, China, Australia
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Breast Cancer

Israel, Italy, Spain, United States, Belgium, Czechia, Australia, United Kingdom, Korea, Republic of, Romania, France, Taiwan, Latvia
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine
Fudan University

Recruiting

Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer (PTCA199-9)

Pancreatic Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
BeiGene

Completed

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Non-Small Cell Lung Cancer

China
Fudan University

Active, not recruiting

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (SPARK)

Metastatic Breast Cancer

China

3

Subscribe